Vantage logo

What’s in a p value?

Biotech’s propensity to manipulate clinical datasets to show significance where none exists must be curbed, but a plan to raise the p value threshold looks like a way of…

Vantage logo

Tyk2 reaches tipping point

Bristol-Myers Squibb is ahead in a new oral class that could bring similar efficacy to current injectables for autoimmune diseases – but Pfizer seems less keen.